SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending following an FDA advisory committee's unanimous vote of confidence in its mRNA-1010 flu vaccine for adults aged 50 and older. The community is actively discussing the potential for a successful product launch, a broader shift into oncology, and institutional positioning through call spread strategies despite ongoing polarized debate regarding vaccine efficacy.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh conflicting narratives between bullish speculation of an imminent tenant announcement and intense corporate governance drama surrounding its former CEO. Community sentiment remains polarized, with many monitoring for signs of major infrastructure deals or institutional accumulation while others warn of risks associated with the ongoing leadership disputes and lack of verified operational revenue.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is gaining significant market attention as investors weigh promising clinical data for its rezpegaldesleukin (rezpeg) program in atopic dermatitis and alopecia areata against concerns regarding recent equity offerings. Community sentiment remains polarized, with bullish investors betting on the drug's long-term competitive durability and potential for partnerships, while others express frustration over share dilution and the ongoing legal conflict with Eli Lilly.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidia is generating significant investor interest following strong preliminary sales data for its inhaled PAH therapy, Yutrepia, which significantly outperformed analyst expectations. The community is actively discussing the company's growth trajectory and the potential impact of an upcoming, highly anticipated court ruling on its long-term market position and competitive standing against United Therapeutics.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is trending as investors react to a positive revenue outlook and resilient demand, even as the broader airline sector grapples with margin pressure from rising jet fuel costs. The community is actively debating the sustainability of these gains against the backdrop of geopolitical uncertainty and the industry's ability to maintain premium pricing power.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors debate its long-term utility versus its status as a meme-driven asset, with active community discussion centering on potential future integration with Elon Musk's various business ventures. While some participants express frustration over recent price volatility, many others remain focused on accumulation strategies in anticipation of broader market momentum.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing heightened investor focus following the FDA's Breakthrough Therapy Designation for NXC-201 and ongoing anticipation surrounding final clinical trial data. The community is actively discussing the stock's potential as a takeover target, the strategic significance of the company's manufacturing advantages, and the expected path toward a BLA filing later this year.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as investors react to the confirmed start of pre-orders for Grand Theft Auto VI, a major commercial milestone for the highly anticipated title. The community is actively discussing the stock's potential as a long-term revenue engine, with many retail investors expressing strong bullish sentiment regarding the game's massive sales potential and its impact on the company's valuation.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant attention as investors anticipate a major July rollout on Ethereum and potential developments in tokenized equities, leading to active community debate over its role as core infrastructure on the Base chain. While some participants are aggressively accumulating in expectation of a supply-constrained rally, others remain cautious of broader market volatility and potential short-term price retracements.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant community discussion and speculative positioning following an insider purchase by the CEO and continued institutional buy ratings, with investors pointing to a major disconnect between the firm's five consecutive quarters of GAAP profitability and its current market valuation. While some retail investors remain frustrated by the stock's high volatility and sensitivity to geopolitical headlines, the broader conversation centers on the companys potential for a short squeeze and its growth prospects as it continues to onboard major banking partners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adaptive Biotechnologies Business Separation May Unlock Greater Value

William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.read more...

Adaptive Biotechnologies Prices Upsized $300 Mln Sr. Notes Offering

(RTTNews) - Adaptive Biotechnologies Corporation (ADPT) on Wednesday said it has priced an upsized private offering of $300 million of 0% convertible senior notes due 2031...

John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday

Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Buster's and Adaptive Biotechnologies saw after-hours trading dips.read more...

Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

JPMorgan Chase & Co. Lowers Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $19.00

JPMorgan Chase & Co. cut their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an 'overweight' rating for the company in a research note on Wednesday...

Adaptive Biotechnologies (NASDAQ:ADPT) Given Buy Rating at Guggenheim

Guggenheim restated a "buy" rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday...

BTIG Research Reiterates Buy Rating for Adaptive Biotechnologies (NASDAQ:ADPT)

BTIG Research reaffirmed a 'buy' rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday...

Adaptive Biotechnologies (NASDAQ:ADPT) Announces Earnings Results

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of...

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies Q1 Earnings Call Highlights

Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed accelerating momentum in measurable residual disease (MRD) testing, alongside continued...

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Adaptive Biotechnologies Corp

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ADPTAdaptive Biotechnologies Corp

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADPT News